These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 7707373)
1. The crystal structure of cruzain: a therapeutic target for Chagas' disease. McGrath ME; Eakin AE; Engel JC; McKerrow JH; Craik CS; Fletterick RJ J Mol Biol; 1995 Mar; 247(2):251-9. PubMed ID: 7707373 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868 [TBL] [Abstract][Full Text] [Related]
3. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors. Lima AP; dos Reis FC; Serveau C; Lalmanach G; Juliano L; Ménard R; Vernet T; Thomas DY; Storer AC; Scharfstein J Mol Biochem Parasitol; 2001 Apr; 114(1):41-52. PubMed ID: 11356512 [TBL] [Abstract][Full Text] [Related]
4. Cruzain : the path from target validation to the clinic. Sajid M; Robertson SA; Brinen LS; McKerrow JH Adv Exp Med Biol; 2011; 712():100-15. PubMed ID: 21660661 [TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases. Redzynia I; Ljunggren A; Bujacz A; Abrahamson M; Jaskolski M; Bujacz G FEBS J; 2009 Feb; 276(3):793-806. PubMed ID: 19143838 [TBL] [Abstract][Full Text] [Related]
7. Identification of a new class of nonpeptidic inhibitors of cruzain. Brak K; Doyle PS; McKerrow JH; Ellman JA J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536 [TBL] [Abstract][Full Text] [Related]
8. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. Huang L; Brinen LS; Ellman JA Bioorg Med Chem; 2003 Jan; 11(1):21-9. PubMed ID: 12467703 [TBL] [Abstract][Full Text] [Related]
9. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867 [TBL] [Abstract][Full Text] [Related]
10. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. Engel JC; Doyle PS; Palmer J; Hsieh I; Bainton DF; McKerrow JH J Cell Sci; 1998 Mar; 111 ( Pt 5)():597-606. PubMed ID: 9454733 [TBL] [Abstract][Full Text] [Related]
11. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Doyle PS; Zhou YM; Engel JC; McKerrow JH Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625 [TBL] [Abstract][Full Text] [Related]
12. Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. Eakin AE; McGrath ME; McKerrow JH; Fletterick RJ; Craik CS J Biol Chem; 1993 Mar; 268(9):6115-8. PubMed ID: 8454586 [TBL] [Abstract][Full Text] [Related]
13. A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. Brinen LS; Hansell E; Cheng J; Roush WR; McKerrow JH; Fletterick RJ Structure; 2000 Aug; 8(8):831-40. PubMed ID: 10997902 [TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the parasite protease inhibitor chagasin in complex with a host target cysteine protease. Ljunggren A; Redzynia I; Alvarez-Fernandez M; Abrahamson M; Mort JS; Krupa JC; Jaskolski M; Bujacz G J Mol Biol; 2007 Aug; 371(1):137-53. PubMed ID: 17561110 [TBL] [Abstract][Full Text] [Related]
16. Crystal structure of chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi. Figueiredo da Silva AA; de Carvalho Vieira L; Krieger MA; Goldenberg S; Zanchin NI; Guimarães BG J Struct Biol; 2007 Feb; 157(2):416-23. PubMed ID: 17011790 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents. Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888 [TBL] [Abstract][Full Text] [Related]
18. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy. Brak K; Kerr ID; Barrett KT; Fuchi N; Debnath M; Ang K; Engel JC; McKerrow JH; Doyle PS; Brinen LS; Ellman JA J Med Chem; 2010 Feb; 53(4):1763-73. PubMed ID: 20088534 [TBL] [Abstract][Full Text] [Related]
19. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease. Neitz RJ; Bryant C; Chen S; Gut J; Hugo Caselli E; Ponce S; Chowdhury S; Xu H; Arkin MR; Ellman JA; Renslo AR Bioorg Med Chem Lett; 2015 Nov; 25(21):4834-4837. PubMed ID: 26144347 [TBL] [Abstract][Full Text] [Related]
20. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Harth G; Andrews N; Mills AA; Engel JC; Smith R; McKerrow JH Mol Biochem Parasitol; 1993 Mar; 58(1):17-24. PubMed ID: 8459830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]